Luteinizing Hormone Releasing Hormone-RNase A Conjugates Specifically Inhibit the Proliferation of LHRH-Receptor-Positive Human Prostate and Breast Tumor Cells

Molecules and Cells

Volumn 9, Issue 1, 1999, Pages 31-36

  Gho, Yong Song ^a,b   Chae, Chi Bom ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Breast; LHRH; Prostate; RNase A; Tumor

Indexed keywords

GONADORELIN; GONADORELIN RECEPTOR; IMMUNOTOXIN; PANCREATIC RIBONUCLEASE;

ANTIBODY SPECIFICITY; ARTICLE; BREAST TUMOR; DOSE RESPONSE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; PROSTATE TUMOR; TIME;

BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOTOXINS; MALE; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; RECEPTORS, LHRH; RIBONUCLEASE, PANCREATIC; TIME FACTORS;

EID: 0033611598     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Aaron, J. W. and Phillip, B. C. (1981) Extrapituitary actions of gonadotropin-releasing hormone. Endocrinology 2, 437-461.
2. Ahmann, F. R., Citrin, D. L., and DeHaan, H. A. (1987) Zoladex: a sustained release luteinizing hormone-releasing hormone analog for the treatment of advanced prostate cancer. J. Clin. Oncol. 5, 912-917.
3. Bajusz, S., Janaky, T., Csernus, V. J., Bokser, L., Fekete, M., Srkalovic, G., Redding, T. W., and Schally, A. V. (1989) Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 86, 6313-6317.
4. Beintema, J. J., Wietzes, P., Weickman, J. L., and Glitz, D. G. (1984) The amino acid sequence of human pancreatic ribonuclease. Anal. Biochem. 136, 48-64.
5. Bond, M. D. (1988) An in vitro binding assay for angiogenin using placental ribonuclease inhibitor. Anal. Biochem. 173, 166-173.
6. Brinkmann, U., Gallo, M., Brinkmann, E., Kunwar, S., and Pastan, I. (1993) A recombinant active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA 90, 547-551.
7. Denis, L. and Mahler, C. (1990) Prostatic cancer: An overview. Rev. Oncol. 3, 665-677.
8. Fekete, M., Redding, T. W., Comaru-Schally, A. M., Pontes, J. E., Connelly, R. W., Srkalovic, G., and Schally, A. V. (1989) Luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate 14, 191-208.
9. Isaacs, J. T. and Coffey, D. S. (1981) Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the dunning R-3327-H adenocarcinoma. Cancer Res. 41, 5070-5075.
10. Jennes, L., Dalati, B., and Conn, P. M. (1988) Distribution of gonadotropin releasing hormone agonist binding sites in the rat central nervous system. Brain Res. 452, 156-164.
11. Miller, W. R., Scott, W. N., and Morris, R. (1985) Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313, 231-233.
12. Newton, D. L., Nicholls, P. J., Rybak, S. M., and Youle, R. J. (1994) Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv. J. Biol. Chem. 269, 26739-26745.
13. Newton, D. L., Xue, Y., Olson, K. A., Fett, J. W., and Rybak, S. M. (1996) Angiogenin single-chain immunofusions: Influence of peptide linkers and spacers between fusion protein domains. Biochemistry 35, 545-553.
14. Pai, L. H., Batra, J. K., Fitzgerald, D. J., Willingham, M. C., and Pastan, I. (1992) Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys. Cancer Res. 52, 3189-3193.
15. Pai, L. H., FitzGerald, D. J., Tepper, M., Schacter, B., and Pastan, I. (1990) Inhibition of antibody response to Pseudomonas exotoxin and immunotoxin containing Pseudomonas exotoxin by 15-Deoxyspergualin in mice. Cancer Res. 50, 7750-7753.
16. Ramakrishnan, S., Fryxell, D., Mohanraj, D., Olson, M., and Li, B.-Y. (1992) Cytotoxic conjugates containing ribosomal inhibitory proteins. Annu. Rev. Pharmacol. Toxico. 32, 579-621.
17. Rodriguez, G. C., Boente, M. P., Berchuck, A., Whitaker, R. S., O'Briant, K. C., Xu, F., and Bast, R. C. Jr. (1993) The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am. J. Obstet. Gynecol. 168, 228-232.
18. Rybak, S. M., Hoogenboom, H. R., Meade, H. M., Raus, J. C., Schwrtz, D., and Youle, R. J. (1992) Humanization of immunotoxins. Proc. Natl. Acad. Sci. USA 89, 3165-3169.
19. Rybak, S. M., Saxena, S. K., Ackerman, E. J., and Youle, R. J. (1991) Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. J. Biol. Chem. 266, 21202-21207.
20. Sharoni, Y., Bosin, E., Minster, A., Levy, J., and Schally, A. V. (1989) Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 86, 1648-1651.
21. Szepeshazi, K., Scally, A. V., Juhasz, A., Nagy, A., and Janaky, T. (1992) Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo. Anti-Cancer Drugs 3, 109-116.
22. Vitetta, E. S., Krolick, K. A., Miyama-Inaba, M., Cuchely, W., and Uhr, J. W. (1983) Imunotoxins: A new approach to cancer therapy. Science 219, 644-650.